Repression of FasL expression by dipfluzine involves a mechanism of inhibition of NFATc transactivation.
Zhang
Ying-jun
YJ
Department of Pharmacology, Hebei Medical University, Shijiazhuang 050017, China.
Dong
Lan-feng
LF
Yin
Jing-xiang
JX
Jia
Qing-zhong
QZ
Li
Jun-xia
JX
Zhang
Yong-jian
YJ
Wang
Yong-li
YL
D000818:Animals; D001665:Binding Sites; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002936:Cinnarizine / Q000031:analogs & derivatives* / Q000494:pharmacology; D053222:Fas Ligand Protein / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006624:Hippocampus / Q000378:metabolism; D020672:I-kappa B Proteins / Q000378:metabolism; D002546:Ischemic Attack, Transient / Q000378:metabolism*; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D050778:NFATC Transcription Factors / Q000235:genetics / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015533:Transcriptional Activation
D002121:Calcium Channel Blockers; D053222:Fas Ligand Protein; C505662:Faslg protein, rat; D020672:I-kappa B Proteins; D016328:NF-kappa B; D050778:NFATC Transcription Factors; C000606206:Nfkbia protein, rat; D000072000:NF-KappaB Inhibitor alpha; D002936:Cinnarizine; C065758:dipfluzine